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Summary Bone marrow transplantation (BMT) is one of the promising methods of treatment
of hematologic malignancy. However, it has a variety of complications since it involves fatal
doses of anti-cancer drugs and radiation during the conditioning period. Among the various
complications of BMT, pulmonary hypertension is rare and its pathogenesis is poorly understood.
A 35-year-old female with acute myeloid leukemia (AML) presented with pulmonary hyper-
tension after BMT. Although she exhibited severe dyspnea on admission, her general condition
markedly improved after oxygen therapy and treatment with warfarin and beraprost sodium.disease;
Chemotherapy;
Leukemia
Her pulmonary hypertension was diagnosed as pulmonary arterial hypertension (PAH) related to
BMT. Although PAH has only rarely been reported as a complication of BMT, we present here for
the ﬁrst time an adult patient with PAH associated with BMT who exhibited marked improve-
ment with medical treatment. This case indicates that attention needs to be paid to the clinical
symptoms and physical ﬁndings of PAH as a complication of BMT.
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ntroduction
cute myeloid leukemia (AML) involves a hematopoietic
ransformation characterized by impaired differentiation of
ematopoietic stem or progenitor cells, resulting in abnor-
al growth of a clonal subpopulation of neoplastic cells
r blasts. This malignant alteration may lead to a loss of
ormal hematopoietic function, typically resulting in death
ithin a few weeks to months [1]. Bone marrow transplanta-
ion (BMT), one of the key treatments of AML, dramatically
Published by Elsevier Ireland Ltd. All rights reserved.
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mproves the prognosis of AML. It has been used not only
or patients with AML but also for patients with a wide vari-
ty of hematologic malignancies and benign diseases such as
plastic anemia. However, it features a variety of complica-
ions that result from the chemotherapy and radiotherapy
pplied during the conditioning period. Well-known compli-
ations of BMT include graft-versus host disease (GVHD),
raft failure, interstitial pneumonitis, B-lymphocyte pro-
iferative disorder, and various infections [2]. In contrast,
ulmonary hypertension (PH) is rare as a complication of
MT, and its mechanism of onset remains poorly understood.
PH is a rare progressive disease with poor prognosis.
H features a resting mean pulmonary arterial pressure
PAP) ≥25mmHg, and one of the subgroups of pre-capillary
H, with pulmonary capillary wedge pressure (PCWP)
15mmHg, is classiﬁed as pulmonary arterial hyperten-
ion (PAH) according to the updated clinical classiﬁcation
f PH reported by the Symposium at Dana Point, Cali-
ornia in 2008 [3,4]. One of the prominent changes in
his classiﬁcation from the Venice classiﬁcation is that
ulmonary veno-occlusive disease (PVOD) and pulmonary
apillary hemangiomatosis are moved from a separate cat-
gory into a subcategory of PAH [4]. Although PVOD is the
ost common feature of PH reported in association with
MT, there have been reported few case reports of it [5—9].
We report here a 35-year-old female with AML, who pre-
ented with PH after BMT. Although she had severe dyspnea,
er general condition markedly improved after oxygen ther-
py and treatment with warfarin and beraprost sodium. PAH
as only rarely been reported as a complication of BMT,
nd there has been no report of reversible PAH in associ-
tion with BMT in an adult. We present here for the ﬁrst
ime a patient with PAH after BMT who exhibited marked
mprovement with early medical treatment.
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Figure 1 Chest radiography (A) and chest cH. Nakaoka et al.
ase report
35-year-old woman was diagnosed with AML with mat-
ration (AML M2 in FAB classiﬁcation) in October 2007
t 30-weeks of pregnancy. She was transferred to the
epartment of Hematology and Oncology and Department
f Obstetrics of Osaka University Hospital, and underwent
nduced labor on October 24. After giving birth to her baby,
hemotherapy was begun for induction of remission, fol-
owed by three courses of consolidation therapy.
On March 28, 2008, she received a BMT from an
LA-identical brother while her disease was in complete
emission. Busulphan (36mg/day) was used for 4 days and
yclophosphamide (2700mg/day) for 2 days for conditioning
or BMT. GVHD prophylaxis was performed using the standard
egimen, with cyclosporine and a short course of methotrex-
te. Serum KL-6 levels before and after BMT were 189U/mL
nd 159U/mL, respectively. She had no complication of BMT,
ncluding GVHD, and was discharged two months later (day
8) in a relatively good condition.
Soon after leaving the hospital, however, she gradually
eveloped shortness of breath and was re-hospitalized with
ymptoms of severe heart failure. She was transferred to
he Department of Cardiovascular Medicine on July 2, 2008
day 94). On admission, her heart rate was 108 bpm, her
lood pressure was 92/68mmHg, and oxygen saturation on
oom air was 93%. Physical examination revealed no abnor-
al breath or heart sounds and no leg edema. Arterial blood
as analysis on room air revealed a pO2 62.6mmHg and pCO2
0.6mmHg. Laboratory data on admission are summarized
n Table 1. Brain natriuretic peptide (BNP) was 702 pg/mL
nd serum uric acid (UA) was 7.2mg/dL. Although the elec-
rocardiography (ECG) showed sinus tachycardia of 115 bpm,
hest radiography revealed no cardiomegaly and no signs of
omputed tomography (B) on admission.
PH associated with BMT e25
Table 1 Laboratory data on admission.
WBC 4.70× 103/L BNP 702 pg/mL
RBC 3.74× 103/L PT-INR 1.27
Plt 164× 103/L APTT 28 s
Na 141mequiv./L D-dimer 1.80g/mL
K 4.7mequiv./L HIV Negative
BUN 15mg/dL ANA ≤1:40
Creatinine 0.75mg/dL HHV8 Negative
T-bilirubin 0.8mg/dL Blood analysis
AST 29U/L pCO2 30.6mmHg
ALT 26U/L pO2 62.6mmHg
-GTP 15U/L HCO3 20.3mequiv./L
ALP 102U/L BE −2.6mequiv./L
LDH 235U/L SaO2 91.9%
UA 7.2mg/dL pH 7.435
CRP 0.04mg/dL
WBC, white blood cells; RBC, red blood cells; Plt, platelets; BUN, blood urea nitrogen; T-bilirubin, total bilirubin; AST, aspartate transam-
inase; ALT, alanine transaminase; -GTP, gamma-glutamyl transpeptidase; ALP, alkaline phosphatase; LDH, lactate dehydrogenase; UA,
uric acid; CRP, C-reactive protein; BNP, brain natriuretic peptide; PT-INR, prothrombin-international normalized ratio; APTT, activated
partial thromboplastin time; HIV, human immunodeﬁciency virus; ANA, antinuclear antibody; HHV, human herpes virus; BE, base excess.
Figure 2 Echocardiographic images. (A) On admission, right ventricular systolic pressure was 38mmHg and reverse curvature of
trea
2.74 L/min/m2, mean PAP 35mmHg, and pulmonary vascular
resistance was high (545 dyn s/cm5).
There was no evidence of family history of PAH, colla-
gen disease, chronic hepatitis, portal hypertension, human
Table 2 Right heart catheterization data.
PCWP (7)mmHg
PAP 42/28(35)mmHg
RVP 46/4/10mmHg
RAP (7)mmHg
CO 4.11 L/min
SVR 1888 dyn s/cm5
PVR 545 dyn s/cm5the inter-ventricular septum was noted. (B) After one month of
her tricuspid valve regurgitation had disappeared.
congestive heart failure (Fig. 1A). The result of the 6-min
walking distance (6MWD) test was 237m with 2 L/min nasal
O2 at that time.
Echocardiographic (UCG) examination was performed
prior to BMT, and showed normal cardiac function and nor-
mal right ventricular (RV) pressure. However, her tricuspid
regurgitation-pressure gradient was 38mmHg, the diame-
ter of inferior vena cava was 14mm and reverse curvature
of the inter-ventricular septum was noted at that time.
Left ventricular (LV) contraction was normal (Fig. 2A). Chest
computed tomography (CT) and lung perfusion scintigra-
phy yielded no evidence of pulmonary thromboembolism
(PTE). High-resolution chest CT revealed no sign of cen-
trilobular ground-grass opacities, septal lines, or lymph
node enlargement, which are suggestive for PVOD. In addi-
tion, enhanced CT revealed no pulmonary embolism and
no deep vein thrombosis (Fig. 1B). The results of right
heart catheterization (RHC) are summarized in Table 2.
PCWP was normal (mean PCWP: 7mmHg), cardiac outputtment, left and right ventricular contraction were normal andPCWP, pulmonary capillary wedge pressure; PAP, pulmonary
artery pressure; RVP, right ventricular pressure; RAP, right atrial
pressure; CO, cardiac output; SVR, systemic vascular resistance;
PVR, pulmonary vascular resistance.
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mmunodeﬁciency virus (HIV) infection, or human herpes
irus (HHV)8 infection. She had no evidence of microangio-
athic hemolytic anemia, such as an increase in fragmented
ells or elevated lactate dehydrogenase, which are fre-
uently seen in thrombotic microangiopathy. PH associated
ith respiratory disease and chronic thromboembolic pul-
onary hypertension were further excluded on clinical
rounds. Although the possibility of PAH associated with
rugs and toxins or PVOD could not be excluded at that time,
he was clinically diagnosed with PAH.
Oxygen therapy was started on admission, and
urosemide was simultaneously administered for 2 days
20mg/day). Thereafter, warfarin and beraprost sodium
120g/day) were started. Her general condition improved
oon after initiation of treatment. After one month of
reatment, 6MWD had markedly improved to 395m with
L/min nasal O2, BNP had decreased to 12.9 pg/mL, and
A had also decreased to 4.8mg/dL. UCG examination
evealed normal contraction of the heart, and the abnormal
ontour of the inter-ventricular septum and her tricuspid
alve regurgitation had disappeared (Fig. 2B).
Her general condition was stable in New York Heart Asso-
iation (NYHA) Class II, and she was discharged on August 31,
008 with 1.5mg/day warfarin (prothrombin-international
ormalized ratio: 2.35) and beraprost sodium without oxy-
en therapy. Her BNP and UA were maintained at low levels
BNP 17.2 pg/mL and UA 4.7mg/dL) during a year of obser-
ation in the out-patient clinic without any signs of heart
ailure (NYHA Class I).
iscussion
n the updated Dana Point classiﬁcation, BMT is not char-
cterized as associated with PH. However, drugs- and
oxins-induced PAH are included in the category of PAH [4].
n addition, chemotherapeutic agents are classiﬁed as ‘pos-
ible’ risk factors in the updated lists for PAH [10]. Although
VOD has been reported in association with BMT [5—9],
ttributed in part to direct injury by chemotherapeutic
gents and radiation therapy [11,12], PAH as a complication
f BMT has only rarely been reported. In the present case,
1) PH occurred after BMT, (2) enhanced chest CT scan and
entilation-perfusion scintigraphy did not reveal pulmonary
mbolism, and (3) her clinical course did not deteriorate and
as instead improved with medical treatment. We therefore
iagnosed her PH as PAH related to BMT. However, because
e did not perform lung biopsy, we could not exclude the
ossibility of PVOD, the most common form of PH associated
ith BMT.
Vaksmann et al. described the onset of PAH 5 months
ost-BMT in an 8-year-old girl conditioned with busulphan,
yclophosphamide, and cytarabine [13]. They found no signs
f pulmonary vein involvement that would have suggested
eno-occlusive disease. Open-lung biopsy revealed lesions
ocated exclusively in small pulmonary arteries and arteri-
les with medial hypertrophy and intimal ﬁbrosis associated
ith plexiform lesions, and the pulmonary veins and venules
ere normal. Prostacyclin and diltiazem infusion reduced
ulmonary vascular resistance without signiﬁcant modiﬁca-
ion of systemic vascular resistance or cardiac output, and
he patient was discharged from hospital on oral diltiazem
n
a
o
sH. Nakaoka et al.
nd an anticoagulant in NYHA Class II. Our patient was also
reated with busulphan and cyclophosphamide, and subse-
uently with BMT, and her pulmonary hypertension markedly
mproved with oral prostacyclin and an anticoagulant.
PH has been reported as a complication of BMT in sev-
ral disease groups. Although we excluded PTE in this case,
here are reports of PTE in association with BMT [14].
hether epithelial-alveolar injury induced by chemother-
peutic agents or radiation results in the development of
TE or whether other factors play a role in the pathogenesis
f PTE is unknown. PAH of late onset after BMT has been
eported in association with GVHD [15]. Bronchiolitis oblit-
rans, interstitial pneumonia, and pulmonary ﬁbrosis are
ell-recognized complications of BMT. These disorders are
trongly associated with GVHD, suggesting that the small air-
ays and lung parenchyma are tissues targeted by immune
rocesses in the post-transplant period. However, serum KL-
level after BMT was maintained as normal and chest CT
can in our patient yielded no evidence of pulmonary com-
lications and no signs of GVHD.
Another possible cause of PAH is infection with a vas-
ulotrophic virus, such as HHV8 or HIV [16], which has been
ostulated to play a role in PAH. A reactivation of the viruses
uring post-transplant period has been reported. However,
here was no evidence of HHV8 or HIV infection in our
atient.
Holcomb et al. suggested that PH associated with hema-
ologic malignancies has received considerable attention
s a potential cause of PVOD [17]. In general, the clinical
ourse of PVOD is progressive, and, though there may be
few patients who respond to medical therapy, long-term
urvival is poor and remission has never been reported. The
ause of PVOD remains unclear, although association of it
ith multiple conditions has been reported, and most cases
f it have been diagnosed at autopsy. The actual incidence
f PVOD after BMT is unknown, and it may be more prevalent
han commonly believed, given the difﬁculty in diagnosing
t. It is possible that less severe cases of it are diagnosed
s other illnesses [9]. We therefore cannot exclude the pos-
ibility of chemotherapy-induced injury to the pulmonary
ascular endothelium in this patient, various possibilities
emain, such as PAH associated with drugs and toxins, a less
evere case of PVOD, or other illness. The issue of interest
n this case is the underlying pathological cause of the vas-
ular injury. Although we were unable to clearly determine
he cause of her PH, early appropriate treatment resulted
n improvement of her PH. While the possibility of coinci-
ental overlap with toxicity after BMT cannot be excluded,
he clinical context suggests that injury to pulmonary ves-
els may occur after BMT, and not only in the context of
VHD.
There has been no previous report of reversible PAH in
ssociation with BMT in an adult. In the early stage of human
AH, the disease has two components: pulmonary vasocon-
triction and vascular remodeling. As the disease progresses,
he capacity of the pulmonary vascular bed to dilate and
ecruit unused vasculature is lost. Considering the effective-
ess of the medical treatment, the vasoconstriction of small
rteries may be the pivotal mechanism for the pathogenesis
f PAH in this case.
Whatever its pathogenesis, this case indicates that PH
hould be considered in post-BMT patients with dyspnea
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without evidence of pulmonary parenchymal disease or
bronchiolitis. We have presented here for the ﬁrst time an
adult case of PAH after BMT with marked improvement with
medical treatment. This case indicates that attention must
be paid to the clinical symptoms and physical ﬁndings of PH
as a possible complication of BMT.
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